GU Cancers 2023 | UNITE: efficacy of enfortumab vedotin in advanced urothelial cancer

Vadim Koshkin, MD, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, provides an overview of a retrospective cohort study looking at treatment outcomes with enfortumab vedotin (EV) and other targeted drugs in advanced and metastatic urothelial carcinoma. The objective of UNITE was to confirm whether real-world outcomes with EV would replicate the data observed in clinical trials. Conclusively, the real-world data was consistent with clinical trials. Additionally, the study investigated whether EV benefit extends to subsets of patients excluded from or underrepresented in clinical trials, including patients with significant comorbidities, patients with varying histology and those with and patients with fibroblast growth factor receptor 3 (FGFR3) alterations. Overall, EV had good clinical activity across the various subsets of patients. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.